Francisco discusses the potential benefits of methylene blue as a neuroprotective agent and its application in emergency medicine. He highlights the challenges of commercialization due to lack of profitability and the influence it has on research funding. Peter expresses his concern about the lack of clinical trials and the need for further investigation into this promising agent.
